3 Stocks Pushing The Drugs Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Drugs industry as a whole closed the day down 2.0% versus the S&P 500, which was down 0.8%. Laggards within the Drugs industry included Aoxing Pharmaceutical ( AXN), down 10.4%, Oragenics ( OGEN), down 8.0%, ImmuCell ( ICCC), down 2.1%, Prima Biomed ( PBMD), down 2.9% and Celsus Therapeutics ( CLTX), down 5.2%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Incyte ( INCY) is one of the companies that pushed the Drugs industry lower today. Incyte was down $1.91 (3.9%) to $47.41 on average volume. Throughout the day, 1,039,621 shares of Incyte exchanged hands as compared to its average daily volume of 962,900 shares. The stock ranged in price between $46.73-$49.55 after having opened the day at $49.23 as compared to the previous trading day's close of $49.32.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs primarily for oncology and inflammation. Incyte has a market cap of $8.2 billion and is part of the health care sector. Shares are down 2.6% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Incyte a buy, no analysts rate it a sell, and 1 rates it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings rates Incyte as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.

Highlights from TheStreet Ratings analysis on INCY go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 1334.2% when compared to the same quarter one year ago, falling from -$2.57 million to -$36.87 million.
  • Net operating cash flow has significantly decreased to -$14.56 million or 280.13% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • INCYTE CORP has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past year. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, INCYTE CORP reported poor results of -$0.54 versus -$0.36 in the prior year. This year, the market expects an improvement in earnings (-$0.40 versus -$0.54).
  • The revenue fell significantly faster than the industry average of 43.1%. Since the same quarter one year prior, revenues slightly dropped by 2.0%. Weakness in the company's revenue seems to have hurt the bottom line, decreasing earnings per share.
  • Compared to its closing price of one year ago, INCY's share price has jumped by 34.65%, exceeding the performance of the broader market during that same time frame. Regarding the future course of this stock, we feel that the risks involved in investing in INCY do not compensate for any future upside potential, despite the fact that it has seen nice gains over the past 12 months.

You can view the full analysis from the report here: Incyte Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Clovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers

Cramer: There Should Be More Takeovers Where These Came From

Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers

Eli Lilly Shares Lower After Update on Rheumatoid Arthritis Drug

How Competition Drives Stocks Nowhere: Cramer's 'Mad Money' Recap (Tuesday 7/11/17)